



GUIDELINE

Open Access



Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union

Jürgen Rehm^{1,2,3,4,5,6} , Peter Anderson^{7,8}, Jose Angel Arbesu Prieto^{9,10}, Iain Armstrong¹¹, Henri-Jean Aubin¹², Michael Bachmann¹³, Nuria Bastida Bastus¹⁴, Carlos Brotons¹⁵, Robyn Burton¹¹, Manuel Cardoso¹⁶, Joan Colom¹⁷, Daniel Duprez¹⁸, Gerrit Gmel^{1,19,20}, Antoni Gual²¹, Ludwig Kraus^{22,23}, Reinhold Kreutz²⁴, Helena Liira^{25,26}, Jakob Manthey^{6*} , Lars Møller²⁷, Ľubomír Okruhlica²⁸, Michael Roerecke^{1,2,3}, Emanuele Scafato^{29,30}, Bernd Schulte³¹, Lidia Segura-Garcia¹⁷, Kevin David Shield¹, Cristina Sierra³², Konstantin Vyshinskiy³³, Marcin Wojnar³⁴ and José Zarco³⁵

Abstract

Background: Hazardous and harmful alcohol use and high blood pressure are central risk factors related to premature non-communicable disease (NCD) mortality worldwide. A reduction in the prevalence of both risk factors has been suggested as a route to reach the global NCD targets. This study aims to highlight that screening and interventions for hypertension and hazardous and harmful alcohol use in primary healthcare can contribute substantially to achieving the NCD targets.

Methods: A consensus conference based on systematic reviews, meta-analyses, clinical guidelines, experimental studies, and statistical modelling which had been presented and discussed in five preparatory meetings, was undertaken. Specifically, we modelled changes in blood pressure distributions and potential lives saved for the five largest European countries if screening and appropriate intervention rates in primary healthcare settings were increased. Recommendations to handle alcohol-induced hypertension in primary healthcare settings were derived at the conference, and their degree of evidence was graded.

Results: Screening and appropriate interventions for hazardous alcohol use and use disorders could lower blood pressure levels, but there is a lack in implementing these measures in European primary healthcare. Recommendations included (1) an increase in screening for hypertension (evidence grade: high), (2) an increase in screening and brief advice on hazardous and harmful drinking for people with newly detected hypertension by physicians, nurses, and other healthcare professionals (evidence grade: high), (3) the conduct of clinical management of less severe alcohol use disorders for incident people with hypertension in primary healthcare (evidence grade: moderate), and (4) screening for alcohol use in hypertension that is not well controlled (evidence grade: moderate). The first three measures were estimated to result in a decreased hypertension prevalence and hundreds of saved lives annually in the examined countries.

Conclusions: The implementation of the outlined recommendations could contribute to reducing the burden associated with hypertension and hazardous and harmful alcohol use and thus to achievement of the NCD targets. Implementation should be conducted in controlled settings with evaluation, including, but not limited to, economic evaluation.

Keywords: Hypertension, Blood pressure, Alcohol use, Primary healthcare, Europe, Screening, Management, Recommendations

* Correspondence: jakob.manthey@tu-dresden.de

⁶Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany

Full list of author information is available at the end of the article



Background

Alcohol and hypertension as risk factors for non-communicable diseases (NCDs)

In May 2013, the World Health Organization (WHO) adopted a Global Action Plan for the Prevention and Control of Non-communicable Diseases for the period 2013–2020. The main target [1] comprises a 25% reduction in the risk of premature mortality from cardiovascular diseases, cancer, diabetes, or chronic respiratory diseases. To achieve this overall target, a number of individual targets for risk factors have been established, including, but not limited to, at least a 10% reduction in the harmful use of alcohol and a 25% reduction in the prevalence, or limitation of the increase in the prevalence, of raised blood pressure (BP), according to national circumstances. For countries of the European Union, given the consistently high rates of raised BP over the past decades (e.g., [2]), the 25% reduction of prevalence seems most appropriate [3].

It has been estimated that, if the main targets for risk factors were to be achieved, the overall goal for reduction of premature mortality would be practically reached at the global level [4], and would be exceeded in the European region [5]. The measures proposed to reach the NCD goals are centered around the so-called “best buys” of the WHO, interventions that are not only highly cost-effective but also feasible and appropriate to implement within the respective health systems [6]. Best buys for alcohol comprise taxation increases, restrictions on availability, and a ban on marketing for alcohol use. For hypertension, best buys were more scarce, as only a reduction of salt intake was listed (Appendix 3 of reference [1]) [6–8]. Herein, we will show, using data from five European countries, that screening and interventions for both hazardous and harmful use of alcohol (including alcohol use disorders (AUDs)) and for hypertension in primary healthcare can also lead to public health-relevant reductions of NCDs in Europe, albeit at higher costs than best buys (see point on economic considerations below), as these are individual-level interventions. In addition, this paper will list recommendations from a consensus conference on what should be performed to achieve these reductions.

Methods

Herein, the various stages in preparation for and the activities performed at the consensus conference on “Screening and intervention for harmful alcohol use as a tool to improve the management of hypertension in primary care” will be outlined. The conference took place in Barcelona on 12th November, 2015, by invitation of the Public Health Agency of Catalonia (see Additional file 1: Appendix 1 for the agenda). Catalonia is one of the few jurisdictions in Europe which has integrated yearly screening for alcohol consumption into its primary healthcare plan. The Public Health Agency prepared the conference [9].

Input into the conference

In preparation for the conference, a number of national meetings on its topic were held in Belgium [10], Finland [11], Germany [12], Spain [13], and the UK [14], where presentations of systematic reviews and meta-analyses on causality and the relationship between drinking and BP (see below for a summary) and of systematic reviews on the effects of alcohol intervention on BP (see below for a summary) were held. Further, modelling of the potential impact of primary care interventions on alcohol (technical details on the modelling are listed in Appendix 2, following the stipulations of the GATHER statement [15]) was performed and the results from a survey among primary care physicians on practices concerning alcohol screening and interventions in the management of hypertension [16] were presented. Finally, draft recommendations, prepared on the basis of the abovementioned national meetings, were put forward.

Steps towards consensus

Each draft recommendation was discussed extensively with a preliminary wording. It was agreed that the preliminary wordings would be circulated again to all participants to achieve a final consensus, together with new evidence as available. The second consultation period took place between 20th September and 20th October, 2016. As part of the revision process for the journal article, new evidence was incorporated and there was a third consultation between February 16th and March 1st, 2017.

Grading the recommendations

We based our recommendations on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, which rates the quality of evidence for a particular outcome across studies and does not rate the quality of individual studies [17, 18]. For some recommendations, we took the evidence grades from the respective review of UK National Institute for Health and Care Excellence (NICE), which used the same system to grade the quality of evidence as high, moderate, low, or very low [19].

Results and Discussion

The evidence for alcohol interventions to reduce BP

Several systematic reviews and meta-analyses have shown that alcohol consumption and hypertension are linked in a dose-dependent fashion [20–23], although there may be a threshold level for alcohol consumption below which there are no effects, especially for women [24, 25] (for indirect evidence see [26]). As indicated by the potential threshold, the dose-response relationship is not linear over the full range of alcohol consumption, but for both sexes there is a monotonic dose-response relationship for higher levels of consumption [20, 22, 24], and thus hazardous/harmful drinking and AUDs are closely associated with

elevated BP and/or hypertension [23, 27, 28]. The above described association between hazardous/harmful alcohol consumption and hypertension has been judged as causal [29–31], which means that a logical intervention to reduce BP is to reduce alcohol consumption.

Indeed, several studies support the efficacy and effectiveness of interventions to decrease alcohol consumption in reducing BP levels, with a clinically meaningful decline in BP occurring within a few weeks after reductions in alcohol intake among hypertensive patients [30, 32, 33]. The most comprehensive systematic review and meta-analyses on the effect of alcohol consumption on BP in trials lasting at least 7 days (median duration: 4 weeks) found that, above a baseline drinking level of two drinks per day (drink size was assumed to be 12 g pure alcohol), reduction in alcohol intake was associated with BP reduction [34]. The higher the alcohol consumption at baseline, the greater the reduction in alcohol consumption and in BP levels. The effect could also be shown for people with hypertension [34]. The evidence supporting this intervention is of the highest possible grade [35], as it is based on a systematic review and meta-analyses of randomized controlled trials of interventions to reduce BP in both normotensives and hypertensives, with adequate control groups (for the importance of control groups specifically in the area of interventions for lowering BP see the paper by Patel et al. [36]).

The available evidence has led to standard formulations in European and Canadian guidelines for the management of hypertension in the past decades to address lifestyle factors, including alcohol [37, 38]. In fact, most guidelines, including those from the NICE, stipulate that all patients undergoing assessment or treatment for hypertension should receive initial and periodic lifestyle advice, which includes ascertaining their alcohol consumption and encouraging a reduced intake if they drink hazardously [39].

The situation in the US is slightly different. Although American Society of Hypertension Community Guidelines briefly mention the contribution of alcohol to raised BP [40], the association between alcohol consumption and raised BP is not even mentioned in the main national hypertension guidelines [41] or in the American College of Cardiology/American Heart Association Guidelines regarding lifestyle management to reduce cardiovascular risk [42].

Interventions to reduce alcohol consumption

In the primary care settings, there is significant overlap of hazardous drinking/AUDs (for background see [43]) and hypertension. European evidence suggests that 20.6% of hypertensive men aged 40–65 years have an AUD and 16.7% have alcohol dependence. For hypertensive women aged 40–65 years, it is estimated that 7.2% have an AUD and 5.8% have alcohol dependence [12]. Adding these people to those who do not qualify for an

AUD diagnosis but drink above 60 g or 40 g of pure alcohol per day (for men and women, respectively), resulted in 30.9% or 20.0% of men and women aged 40–65 years, respectively, qualifying for alcohol interventions with hypertension. Compared to those without any AUD, patients with an AUD are estimated to have a 1.5- to 5-fold increased risk of hypertension, with the highest risks for hypertension involving higher levels of alcohol consumption [44–46]. In the above-cited study of more than 13,000 patients in primary healthcare [28, 47], the age-adjusted odds ratio (OR) for hypertension in the age group 40–64 years was 1.59 among those diagnosed with AUD by the treating general practitioner (95% CI 1.35–1.88, $P < 0.001$; own calculations – see Additional file 2: Appendix 2) [47–49].

Looking at the odds from hypertension in the cited study, the age-adjusted OR for an AUD was, of course, similar (OR 1.60, 95% CI 1.35–1.88, $P < 0.001$) because of the symmetry property of OR, and the odds of qualifying for an intervention among people with hypertension was 1.35 (95% CI 1.12–1.58, $P < 0.001$; own calculations; for a description of the study see [47–49]).

Since a reduction in alcohol consumption leads to a decline in BP levels [32, 34], the question becomes whether effective interventions to reduce alcohol consumption are available in primary healthcare. There is ample evidence, based on randomized controlled trials in many countries, that screening and brief advice are effective in reducing alcohol consumption in hazardous and harmful drinkers [50], and that effective psychotherapies and pharmacotherapy plus psychosocial interventions are effective in reducing consumption levels in dependent drinkers [51–55]. Despite this evidence, and its inclusion in some guidelines [37, 39], interventions to reduce alcohol consumption do not play a major role in the management of hypertension at the primary healthcare level in many European countries [16, 56]. One example that illustrates the paucity of activity in primary healthcare is the recent five-country Optimizing Delivery of Health Care Interventions study that recruited 120 primary healthcare units from Catalonia, England, Netherlands, Poland, and Sweden [57]. During the 4-week baseline measurement period, in only 1202 out of 179,954 adult consultations (0.67%) were patients screened for and advised about their hazardous drinking.

Studies have identified a number of potential barriers to the adoption of screening and brief advice in primary healthcare, including the lack of resources, training and support from management, as well as workload [58, 59]. Given this situation, experts in several countries have started to take steps towards better integration of alcohol interventions in primary healthcare [10–14]. Despite obvious differences between healthcare systems, there are clear commonalities in the recommendations made

by the different sets of national experts. These recommendations focus on providing incentives for screening and treatment, better education for primary healthcare providers regarding the link between alcohol and hypertension, and the inclusion of simple alcohol tools in electronic patient records, such that the management of alcohol use becomes standard practice for all patients with hypertension.

The potential in Europe – examples from five countries

While control and management of hypertension is a key element of any European guideline for primary healthcare, most general population surveys show that a large minority of women and the majority of men with hypertension aged 40 to 64 either do not know about their health condition or are not adequately controlled (i.e., they show BP values $\geq 140/90$ mm Hg; see Table 1 for details).

The following models the joint effects of two interventions (see Additional file 2: Appendix 2). First, it is assumed that 50% of the people aged 40–64 years with uncontrolled hypertension (i.e., BP $\geq 140/90$ mm Hg [37, 60, 61]) receive an intervention (in part but not limited to pharmacotherapy [37]), which lowers their BP level to that of people with controlled hypertension. Secondly, it is assumed that, among those with uncontrolled hypertension who are receiving hypertension interventions, 50% of those eligible will also receive either brief advice or a brief intervention for hazardous or harmful alcohol use, or treatment for alcohol dependence. The results are summarized in Table 2.

In each of the countries, the proposed intervention would have a sizeable effect on improving BP levels among 40- to 65-year-old hypertensives and would markedly increase the proportion of people below the threshold 140/90 mm Hg in the general population (for men, between 1.5% and 5.3%; for women, between 1.0% and 2.0%). Both effects are more pronounced in men, which is not surprising, as men have worse control of BP in all countries and, relatedly, they have worse alcohol consumption habits [1] (Table 2).

The next set of calculations measures the impact of the proposed interventions on mortality and burden of disease as measured in disability-adjusted live years (DALYs) in the same age group within 1 year, using the methodology of comparative risk assessment [62, 63] (see Additional file 2: Appendix 2). This limitation for 1 year is consistent with knowledge that brief intervention effects will show some attrition over time [64].

The potential effect of the interventions on reducing mortality would be sizeable. In each of the five countries examined, the reductions of BP and the effects of reduced alcohol would lead to hundreds of deaths avoided within 1 year (Table 3); for instance, in Germany alone, a reduction of 1536 cardiovascular disease deaths, 138 gastrointestinal deaths, and 20 injury deaths. In terms of burden of disease, for Germany, about 86,000 years of life lost due to cardiovascular premature mortality or due to disability in this age group could be avoided, plus another 5500 due to gastrointestinal disease and 3000 due to injury.

This does not even include the effect of reduced alcohol use on other disease categories such as AUDs or cancer. For the latter disease category, the effects would only be seen after decades due to the long time lag [65]. For the other disease categories, lag times are short [66], and the vast majority of deaths will be covered, including liver cirrhosis deaths, where interventions have shown immediate effects [67].

Recommendations

1) Increase screening for hypertension in primary healthcare.

Evidence grade: High. Despite control of hypertension being an integral part of primary healthcare in most European countries, a measurable proportion of the patients with undetected hypertension is evident in all countries, usually among the younger age groups (see Table 1 for details for the five countries modelled). As a result, many countries make specific recommendations for

Table 1 Proportion with hypertension with or without control in large population surveys among 40–64 year olds

	Proportion of people with hypertension ^a		Proportion recognized or in treatment (with or without adequate control) ^b		Fieldwork of main study
	Women	Men	Women	Men	
France	30.4%	46.2%	64.0%	36.1%	2006–2007
Germany	29.6%	36.5%	56.0%	40.1%	2008–2011
Italy	33.2%	42.1%	52.0%	40.4%	2008–2012
Spain	30.0%	42.0%	62.0%	48.1%	2008–2010
UK	22.6%	27.2%	31.2%	23.9%	2006

For definitions and sources, see Additional file 2: Appendix 2

^aHypertension was defined by a blood pressure $\geq 140/90$ mm Hg or by being on hypertensive medication

^bNeither recognition nor initiation of hypertension treatment implies that the patient is adequately controlled (i.e., below 140/90 mm Hg). The number of people without adequately controlled hypertension among those recognized/treated varies from country to country and usually exceeds the number of people with adequate control

Table 2 Blood pressure indicators among people with hypertension before and after the interventions among people with hypertension, 40–64 years old

	Sex	Mean systolic BP ^a		Δ^b	% $\geq 140/90$ mm Hg ^a		Δ^c	General population ^d
		before	after		before	after		
France	W	140.7	138.1	2.5	48%	41%	7%	2.0%
	M	146.3	141.0	5.3	59%	48%	11%	5.3%
Germany	W	141.5	138.5	3.0	49%	42%	7%	2.0%
	M	143.9	139.8	4.2	55%	45%	9%	3.4%
Italy	W	144.7	142.1	2.6	56%	51%	6%	1.8%
	M	144.2	139.7	4.4	55%	45%	10%	4.0%
Spain	W	146.0	144.6	1.4	60%	57%	3%	1.0%
	M	146.8	144.9	1.9	62%	57%	4%	1.8%
UK	W	141.5	139.5	2.0	50%	45%	5%	1.1%
	M	145.4	142.8	2.5	58%	52%	5%	1.5%

For definitions and sources, see Additional file 2: Appendix 2 [109]

^aBlood pressure (BP) in mm Hg among people with hypertension, defined by a BP $\geq 140/90$ mm Hg or by being on hypertensive medication

^bDifference between before and after interventions in mm Hg

^c% difference between before and after interventions

^d% increase of people below the threshold of 140/90 mm Hg in the general population

Table 3 Lives saved and disability-adjusted life years avoided in major disease categories within 12 months attributable to the interventions among people with hypertension, 40–64 years old

Deaths		Cardiovascular disease			Gastrointestinal disease		Injury
		Total	Attributable to IHD	Attributable to stroke	Total	Attributable to liver cirrhosis	
France	W	111	25	47	12	11	3
	M	1041	443	276	109	88	30
Germany	W	275	83	98	25	22	2
	M	1261	633	246	113	100	18
Italy	W	158	42	57	10	9	1
	M	805	389	180	98	82	15
Spain	W	50	16	22	4	3	1
	M	301	164	76	48	38	8
UK	W	77	27	29	25	24	2
	M	378	220	78	84	75	11
DALYs							
France	W	10,590	2850	5189	456	417	418
	M	56,844	23,237	19,335	4235	3710	2914
Germany	W	21,179	7042	8703	1007	943	599
	M	64,840	31,245	16,983	4491	4022	2379
Italy	W	15,543	4948	5872	489	452	536
	M	47,273	21,992	13,020	4305	3777	2491
Spain	W	4764	1483	2100	181	159	233
	M	16,419	8086	5007	1934	1660	1198
UK	W	4860	1648	2117	1012	936	495
	M	18,354	9581	5348	3394	3033	1632

For definitions and sources, see Additional file 2: Appendix 2

IHD ischemic heart disease, DALYs disability-adjusted life years

the screening of hypertension via regular measurement of BP (for example, for the UK see the Quality and Outcomes Framework indicator set by the National Health Service; for underlying evidence see reviews [68–70] or large trials [71]). The evidence for these screening efforts was graded as the highest possible quality, and current explorations are mainly concerned with best techniques for assessing BP [68, 72].

- 2) *Increase screening and brief advice on hazardous and harmful drinking for people with newly detected hypertension from physicians, nurses, and other healthcare professionals in primary healthcare.*

Evidence grade: High. Even though this recommendation has not been implemented into clinical practice in most countries, the evidence grade from controlled clinical studies has been evaluated as consistently high (see [50, 64, 73] for effectiveness of brief advice for reducing drinking; see [32, 34] for meta-analyses of alcohol interventions on BP, including on BP levels of people with hypertension).

- 3) *Treatment for less severe alcohol use disorders in people with incident hypertension should be conducted in primary healthcare, including but not limited to pharmacologically assisted treatment.*

Evidence grade: Moderate. While there are some recommendations for treatment of less severe AUDs in primary healthcare [74–76] and randomized controlled trials on specific elements of this strategy (e.g., effectiveness of medication-assisted treatment [77, 78]), the strategy has not been systematically tested in randomized controlled clinical trials. Additionally, to date, it has not been tested specifically for people with hypertension in primary healthcare, even though there is evidence from randomized controlled trials that treatment for AUDs can lower BP [33, 79–81]. This is to be expected, as AUDs are strongly associated with hazardous or harmful drinking levels [43, 82], and abstinence or reduction of drinking is the main outcome variable in most of these trials [83].

- 4) *Screen for alcohol use in hypertension that is not well controlled.*

Evidence grade: Moderate. Current guidelines for the management for treatment-resistant hypertension, comprising approximately 8–12% of patients with uncontrolled BP [84], emphasize screening of alcohol use and reduction of hazardous or harmful drinking levels [85, 86]. However, there are no randomized clinical trials underlying this recommendation; it is supported mainly by biological plausibility and, in a recent assessment [86], the

relevant committee of the French Society for Hypertension gave it a moderate evidence grade.

Economic considerations

Thus far, we have only considered estimated effects of implementing both interventions, indicating public health-relevant effects on BP and premature mortality (as all calculations were restricted to people aged 40–65 years). Others have shown effects on wider outcomes as well (see [34] for effects on BP-attributable hospitalizations; Organisation for Economic Co-operation and Development [87] for estimating and comparing effects on alcohol interventions on disease burden). For any change in healthcare systems, information about costs are also necessary, as effective interventions may not be taken up if they are not cost-effective. A recent systematic review showed that brief interventions in primary healthcare have also been shown to be cost-effective [88]. In addition, Angus et al. [89] estimated, by modelling potential effects of implementing screening and brief interventions for hazardous or harmful drinking, that these programs were likely to be cost-effective in 24 out of 28 European Union countries and cost-saving in 50% of these. They concluded that implementing national alcohol intervention programs in primary healthcare would be a cost-effective means to reduce health burden. However, it should be noted that the work of Angus et al. [89] was not limited to the consequences mediated by BP, but included all health consequences.

Given these numbers, and bearing in mind that there is only one best buy for hypertension (Appendix 3 of [1]) and, further, that the three best buys for alcohol have been rarely considered by decision-makers given the strong impact of economic operators and the fear that taxation increases and availability restrictions would prove unpopular with many voters [90], implementing alcohol interventions for people with newly detected hypertension seems an attractive and feasible option to improve public health at relatively low, or for some jurisdictions, no overall costs.

Potential for implementation and conclusions

All of the four recommendations have been chosen as measurable, achievable, and realistic for implementation in primary healthcare. Obviously, as with all recommendations, implementations should be carefully evaluated. While we have laid out the economic arguments for implementing the recommendations, these are currently based on assumptions and different modelling approaches. More controlled approaches with randomization should be used to study the effects of the recommendations. Moreover, evaluations, including but not limited to economic evaluations [91], are necessary to create sustainable policies, which could be defended in times of scarce resources.

During implementation, priority should be given to the integration of routine screening for alcohol (recommendation 2) and interventions for hazardous and harmful drinking (recommendation 2) and AUDs (recommendation 3) into the management of hypertension. Improved training and better remuneration systems, specifically adapted to the different healthcare systems, are crucial [57]. Some of the current steps in this direction are promising, and we hope that the reasoning and recommendations of this consensus paper can provide further important momentum to move European healthcare systems in this direction.

Additional file

Additional file 1: Appendix 1. Workshop agenda. (PDF 148 kb)

Additional file 2: Appendix 2. Methodology [92–108]. (PDF 824 kb)

Abbreviations

AUDs: Alcohol use disorders; BP: Blood pressure; DALYs: Disability-adjusted life years; NCDs: Non-communicable Diseases; NICE: National Institute for Health and Care Excellence; WHO: World Health Organization

Acknowledgements

It should be noted that the views reported in this paper do not necessarily represent the views of the authors' employing organizations.

Funding

The workshop entitled "Screening and intervention for harmful alcohol use as a tool to improve the management of hypertension in primary care", held on November 12, 2015, in Barcelona, Spain, was financially supported by Lundbeck (in providing travel allowances for some participants). An agenda of the workshop can be found in Additional file 1: Appendix 1.

Availability of data and materials

Data sources used for modelling are referenced. No primary data were used.

Authors' contributions

All authors, except for DD, GG, JM, JAAP, and KDS, participated at the "Screening and intervention for harmful alcohol use as a tool to improve the management of hypertension in primary care" conference in Barcelona. The discussions during this conference were condensed and compiled by JR, which resulted in the first draft of the manuscript. DD, GG, JM, JAAP, and KDS contributed critical content to this manuscript. All authors contributed to and approved of the final version.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

JR reports grants, personal fees and serving as board member (Nalmefene up to 2014) for Lundbeck. PA reports no competing interests. JAAP reports grants and personal fees from Lundbeck. IA reports no competing interests. H-JA reports serving as board member for Pfizer, D&A Pharma, Ethypharm, and Lundbeck, and receiving sponsorships, speaker honoraria and consultancy fees from Bioprojet, D&A Pharma, Ethypharm, Lundbeck, Merck-Serono, Novartis, and Pfizer. MB reports consulting fees received from Lundbeck (through consulting business Copentown) for organisational and process support in connection with the project. Copentown, which is owned by MB, also has other pharmaceutical/healthcare clients. NBB reports funding from Lundbeck for a research project on alcohol. CB reports consulting fees from Lundbeck. RB reports no competing interests. MC reports no competing interests. JC reports sponsorship from Lundbeck to attend scientific meetings. DD received consultant fee from Lundbeck. GG reports no competing interests.

AG reports grants and personal fees from Lundbeck and D&A Pharma, grants from TEVA, and personal fees from Abbvie. LK reports funding from Lundbeck for a research project on alcohol. RK received honoraria for consultancy, lectures and support for research from Bayer Pharma, Berlin-Chemie Menarini, Bristol-Myers Squibb, Daiichi Sankyo, Lundbeck, and Servier. HL reports consultancy fee from Lundbeck. JM reports personal fees from Lundbeck. LM reports no competing interests. LO reports no competing interests. MR reports no competing interests. ES reports sponsorship to attend scientific meetings from Lundbeck. BS reports no competing interests. LS-G reports sponsorship from Lundbeck to attend one scientific meeting. KDS reports no competing interests. CS reports sponsorship to attend scientific meetings from Lundbeck. KV reports no competing interests. MW reports personal fees from AOP Orphan, Berlin Chemie, Janssen, Lundbeck, D&A Pharma, Reckitt Benckiser. JZ reports personal fees from Lundbeck, and consultancy fees and salaries from Menarini, Lilly and Gilead.

Author details

¹Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Canada. ²Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada. ³Addiction Policy, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. ⁴Institute of Medical Science, University of Toronto, Faculty of Medicine, Medical Sciences Building, Toronto, Canada. ⁵Department of Psychiatry, University of Toronto, Toronto, Canada. ⁶Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany. ⁷Substance Use, Policy and Practice, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK. ⁸Alcohol and Health, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands. ⁹Primary Care Center La Eria, Oviedo, Spain. ¹⁰Primary Care Spanish Society SEMERGEN, Madrid, Spain. ¹¹Health and Wellbeing Directorate, Public Health England, London, UK. ¹²CESP, University Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, APHP, Hôpitaux Universitaires Paris-Sud, Villejuif, France. ¹³Copentown Healthcare Consultants, Cape Town, South Africa. ¹⁴Primary Health Center, Raval Nord, Barcelona, Spain. ¹⁵Sardenya Primary Health Care Center, Biomedical Research Institute Sant Pau, Barcelona, Spain. ¹⁶General Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), Lisbon, Portugal. ¹⁷Program on Substance Abuse, Public Health Agency of Catalonia, Department of Health, Government of Catalonia, Barcelona, Spain. ¹⁸Cardiovascular Division, School of Medicine, University of Minnesota, Minneapolis, USA. ¹⁹Implant Systems Group, National ICT Australia, Eveleigh, Australia. ²⁰Faculty of Engineering, University of New South Wales, Sydney, Australia. ²¹Addictions Unit, Psychiatry Department, Neurosciences Institute, Hospital Clinic, IDIBAPS, Barcelona, Spain. ²²IFT Institut für Therapieforchung, Munich, Germany. ²³Centre for Social Research on Alcohol and Drugs (SoRAD), Stockholm University, Stockholm, Sweden. ²⁴Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany. ²⁵General Practice, School of Primary, Aboriginal and Rural Health Care, University of Western Australia, Perth, Australia. ²⁶University of Helsinki, Department of General Practice, and Helsinki University Central Hospital, Unit of Primary Health Care, Helsinki, Finland. ²⁷Division of Noncommunicable Diseases through the Life Course, WHO Regional Office for Europe, Copenhagen, Denmark. ²⁸Centrum pre Liecbu Drogovych Zavislosti, Bratislava, Slovakia. ²⁹National Observatory on Alcohol, National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy. ³⁰Società Italiana di Alcolologia (SIA), Italian Society of Alcoholology, Bologna, Italy. ³¹Centre for Interdisciplinary Addiction Research, Hamburg University, Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany. ³²Hypertension and Vascular Risk Unit, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. ³³Research Institute on Addictions, Federal Medical Research Centre for Psychiatry and Narcology n.a. V. Serbsky, Moscow, Russia. ³⁴Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland. ³⁵Drugs Intervention Group, semFYC, Ibiza Primary Health Care Center, Madrid, Spain.

Received: 24 October 2016 Accepted: 22 August 2017

Published online: 28 September 2017

References

1. World Health Organization. Global Action Plan for the Prevention and Control of NCDs 2013–2020. Geneva: WHO; 2013.

2. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. *JAMA*. 2003;289:2363–9.
3. World Health Organization. A global brief on hypertension. Geneva: WHO; 2013.
4. Kontis V, Mathers CD, Rehm J, Stevens GA, Shield KD, Bonita R, et al. Contribution of six risk factors to achieving the “25 × 25” NCD mortality reduction target. *Lancet*. 2014;384:427–37.
5. Kontis V, Mathers CD, Bonita R, Stevens GA, Rehm J, Shield KD, et al. Regional contributions of six preventable risk factors to achieving the 25 × 25 non-communicable disease mortality reduction target: a modelling study. *Lancet Glob Health*. 2015;3:e746–57.
6. World Economic Forum & World Health Organization. From burden to “best buys”: Reducing the economic impact of non-communicable diseases in low- and middle-income countries. Davos: World Economic Forum; 2011.
7. Chisholm D, Rehm J, van Ommeren M, Monteiro M. Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. *J Stud Alcohol*. 2004;65:782–93.
8. World Health Organization. Discussion Paper: Prevention and Control of NCDs: Priorities for Investment. Moscow: First Global Ministerial Conference on Healthy Lifestyles and Noncommunicable Disease Control; 2011.
9. Department of Health. Health Plan of Catalonia 2016–2020. Barcelona: Government of Catalonia; 2016. http://salutweb.gencat.cat/ca/el_departament/Pla_salut/pla-de-salut-2016-2020/linies-estrategiques/. Accessed 22 Feb 2017.
10. Collart F, de Timary P, Dom G, Dor BD, Duprez D, Lengelé JP, et al. Alcohol-induced hypertension: an important healthcare target in Belgium. *Acta Clin Belg*. 2015;70:389–95.
11. Aalto M, Jula A, Keinänen-Kiukkaanniemi S, Liira H, Räsänen K, Rehm J, et al. Alkoholin käytön suitsiminen vähentää kohonneen verenpaineen haittoja. Alkoholiselontanto, mini-interventiot ja riippuvuuden hoito voisivat merkittävästi vähentää kohonneen verenpaineen sairastavien määrää. [Tackling alcohol consumption reduces high blood pressure damage. Alcohol Screening, brief-interventions and addiction treatment could significantly reduce elevated blood pressure in patients]. *Suomen Lääkärilehti*. 2017;35:2177–2179A.
12. Rehm J, Gmel G, Kiefer F, Kreutz R, Kugler J, Müller-Walther M, et al. Verbesertes Hypertonie-Management durch Alkohol-Screening und Folgeinterventionen in der Hausarztpraxis. *Deu Med Wochenschr*. 2014;139:2457–62.
13. Gual A, Zarco J, Colom JF, Rehm J. Cribado precoz e intervención breve en el consumo perjudicial de alcohol para mejorar el tratamiento de la hipertensión arterial en atención primaria. *Med Clin Barcelona*. 2016;146:81–5.
14. Ballard J, Brown A, D’Agnone O, Grimm C, Gunson B, Harris L et al. Under Pressure: Tackling two of the most common preventable health harms in the UK; high blood pressure and excessive alcohol consumption. Lundbeck. 2015. https://www.alcohollearningcentre.org.uk/_assets/Treat%2015%20Under%20Pressure.pdf. Accessed 7 Oct 2016.
15. Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. *Lancet*. 2016;388:e19–23.
16. Rehm J, Angel J, Prieto A, Beier M, Duhot D, Rossi A, et al. The role of alcohol in the management of hypertension in patients in European primary health care practices – a survey in the largest European Union countries. *BMC Fam Prac*. 2016;17:130.
17. The GRADE Working Group. What is GRADE? 2016. <http://www.gradeworkinggroup.org/>. Accessed 7 Oct 2016.
18. U.S. Department of Health and Human Services. Lifestyle Interventions to Reduce Cardiovascular Risk. 2013. <https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/lifestyle>. Accessed 17 Feb 2017.
19. National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Clinical Guideline Centre; 2012.
20. Taylor B, Irving HM, Baliunas D, Roerecke M, Patra J, Mohapatra S, et al. Alcohol and hypertension: gender differences in dose-response relationships determined through systematic review and meta-analysis. *Addiction*. 2009;104:1981–90.
21. Briassoulis A, Agarwal V, Messerli FH. Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. *J Clin Hypertens*. 2012;14:792–8.
22. O’Keefe JH, Bhatti SK, Bajwa A, DiNicolantonio JJ, Lavie CJ. Alcohol and cardiovascular health: the dose makes the poison...or the remedy. *Mayo Clin Proc*. 2014;89:382–93.
23. Puddey IB, Beilin LJ. Alcohol is bad for blood pressure. *Clin Exp Pharmacol Physiol*. 2006;33:847–52.
24. Klatsky AL, Gunderson E. Alcohol and hypertension. In: Mohler ER, Townsend RR, editors. *Advanced Therapy in Hypertension and Vascular Disease*. Hamilton: BC Decker Inc.; 2006. p. 108–17.
25. Sesso HD, Cook NR, Buring JE, Manson JE, Gaziano JM. Alcohol consumption and the risk of hypertension in women and men. *Hypertension*. 2008;51:1080–7.
26. Klatsky AL, Gunderson E, Kipp H, Udaltsova N, Friedman GD. Higher prevalence of systemic HTN among moderate alcohol drinkers: exploring the role of under-reporting. *J Stud Alcohol*. 2006;67:421–8.
27. Saunders JB, Paton A, Beevers DG. Alcohol-induced hypertension. *Lancet*. 1981;2:653–6.
28. Rehm J, Allamani A, Elekes Z, Jakubczyk A, Landsmane I, Manthey J, et al. General practitioners recognizing alcohol dependence: a large cross-sectional study in six European countries. *Ann Fam Med*. 2015;13:28–32.
29. Rehm J, Gmel SG, Gmel GE, Hasan OSM, Imtiaz S, Popova S, et al. The relationship between different dimensions of alcohol use and the burden of disease – an update. *Addiction*. 2017;112(6):968–1001.
30. Saunders JB. Alcohol: an important cause of hypertension. *BMJ*. 1987;294:1045–6.
31. Rehm J, Baliunas D, Borges GL, Graham K, Irving HM, Kehoe T, et al. The relation between different dimensions of alcohol consumption and burden of disease – An overview. *Addiction*. 2010;105:817–43.
32. Xin X, He J, Frontini MG, Ogden LG, Motsamai OJ, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2001;38:1112–7.
33. Stewart SH, Latham PK, Miller PM, Randall P, Anton RF. Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. *Addiction*. 2008;103:1622–8.
34. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis of trial data. *Lancet Public Health*. 2016;2:e108–20.
35. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0. The Cochrane Collaboration. 2011. <http://handbook-5-1.cochrane.org/>. Accessed 15 Feb 2017.
36. Patel HC, Hayward C, Ozdemir BA, Rosen SD, Krum H, Lyon AR, et al. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. *Hypertension*. 2015;65:401–6.
37. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2013;31:1281–357.
38. Campbell NR, Ashley MJ, Carruthers SG, Lacourcière Y, McKay DW. Lifestyle modifications to prevent and control hypertension. 3. Recommendations on alcohol consumption. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. *Can Med Assoc J*. 1999;160:513–20.
39. National Clinical Guideline Centre. Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London: Royal College of Physicians (UK) - National Clinical Guideline Centre; 2011.
40. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens*. 2014;32:3–15.
41. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311:507–20.
42. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63:2960–84.
43. Rehm J, Marmet S, Anderson P, Gual A, Kraus L, Nutt DJ, et al. Defining substance use disorders: do we really need more than heavy use? *Alcohol Alcohol*. 2013;48:633–40.
44. Li TK. Quantifying the risk for alcohol-use and alcohol-attributable health disorders: present findings and future research needs. *J Gastroenterol Hepatol*. 2008;23:52–8.

45. Klatsky AL, Koplik S, Gunderson E, Kipp H, Friedman GD. Sequelae of systemic hypertension in alcohol abstainers, light drinkers, and heavy drinkers. *Am J Cardiol*. 2006;98:1063–8.
46. Miller PM, Anton RF, Egan BM, Basile J, Nguyen SA. Excessive alcohol consumption and hypertension: clinical implications of current research. *J Clin Hypertens*. 2005;7:346–53.
47. Manthey J, Gual A, Jakubczyk A, Pieper L, Probst C, Struzzo P, et al. Alcohol use disorders in Europe: a comparison of general population and primary health care prevalence rates. *J Subst Use*. 2016;21:478–84.
48. Rehm J, Allamani A, Elekes Z, Jakubczyk A, Manthey J, Probst P, et al. Alcohol dependence and treatment utilization in Europe - a representative cross-sectional study in primary care. *BMC Fam Prac*. 2015;16:90.
49. Rehm J, Manthey J, Struzzo P, Gual A, Wojnar M. Who receives treatment for alcohol use disorders in the European Union? A cross-sectional representative study in primary and specialized health care. *Euro Psych*. 2015;30:885–93.
50. Kaner EF, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, et al. Effectiveness of brief alcohol interventions in primary care populations. *Cochrane Database Syst Rev*. 2007;18:CD004148.
51. Miller WR, Wilbourne PL. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. *Addiction*. 2002;97:265–77.
52. Martin G, Rehm J. The effectiveness of psychosocial modalities in the treatment of alcohol problems in adults: a review of the evidence. *Can J Psychiatry*. 2012;57:350–8.
53. Mann K, Bladström A, Torup L, Gual A, Van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. *Biol Psychiat*. 2013;73:706–13.
54. Gual A, He Y, Torup L, Van Den Brink W, Mann K, ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. *Eur Neuropsychopharmacol*. 2013;23:1432–42.
55. van den Brink W, Sørensen P, Torup L, Mann K, Gual A, SENSE Study Group. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. *J Psychopharmacol*. 2014;28:733–44.
56. Kraus L, Schulte B, Manthey J, Rehm J. Alcohol screening and alcohol interventions among patients with hypertension in primary health care: An empirical survey of German general practitioners. *Addict Res Theory*. 2017; 25(4):285–92.
57. Anderson P, Bendtsen P, Spak F, Reynolds J, Drummond C, Segura L, et al. Improving the delivery of brief interventions for heavy drinking in primary health care: outcome results of the Optimizing Delivery of Health Care Intervention (ODHIN) five-country cluster randomized factorial trial. *Addiction*. 2016;111:1935–45.
58. Johnson M, Jackson R, Guillaume L, Meier P, Goyder E. Barriers and facilitators to implementing screening and brief intervention for alcohol misuse: a systematic review of qualitative evidence. *J Public Health*. 2011;33:412–21.
59. Anderson P, Wojnar M, Jakubczyk A, Gual A, Segura L, Sovinova H, et al. Managing alcohol problems in general practice in Europe: results from the European ODHIN survey of general practitioners. *Alcohol Alcohol*. 2014;49:531–9.
60. Swales JD. Guidelines on guidelines. *J Hypertens*. 1993;11:899–903.
61. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). *Arch Intern Med*. 1993;153:154–83.
62. Ezzati M, Lopez A, Rodgers A, Murray CJL. Comparative quantification of health risks. Global and regional burden of disease attributable to selected major risk factors. Geneva: WHO; 2004.
63. Rehm J, Imtiaz S. A narrative review of alcohol consumption as a risk factor for global burden of disease. *Subst Abuse Treat Prev Policy*. 2016;11:37.
64. O'Donnell A, Anderson P, Newbury-Birch D, Schulte B, Schmidt C, Reimer J, et al. The impact of brief alcohol interventions in primary healthcare: a systematic review of reviews. *Alcohol Alcohol*. 2014;49:66–78.
65. Rehm J, Patra J, Popova L. Alcohol drinking cessation and its effect on oesophageal and head and neck cancers: a pooled analysis. *Int J Cancer*. 2007;121:1132–7.
66. Holmes J, Meier PS, Booth A, Guo Y, Brennan A. The temporal relationship between per capita alcohol consumption and harm: a systematic review of time lag specifications in aggregate time series analyses. *Drug Alcohol Depend*. 2012;123:7–14.
67. Zatonski W, Sulkowska U, Manczuk M, Rehm J, Lowenfels AB, La Vecchia C. Liver cirrhosis mortality in Europe, with special attention to central and eastern Europe. *Eur Addict Res*. 2010;16:193–201.
68. Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Smith N, et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: Screening for High Blood Pressure in Adults: A Systematic Evidence Review for the US Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality; 2014.
69. U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med*. 2007;147:783–6.
70. Sheridan S, Pignone M, Donahue K. Screening for high blood pressure: a review of the evidence for the U.S. Preventive Services Task Force. *Am J Prev Med*. 2003;25:151–8.
71. Kaczorowski J, Chambers LW, Dolovich L, Paterson JM, Karwalajtys T, Giernan T, et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP). *BMJ*. 2011;342:d442.
72. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. *BMJ*. 2011;342:d3621.
73. National Institute for Health and Clinical Excellence. Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. London: NICE; 2011.
74. Day E, Copello A, Hull M. Assessment and management of alcohol use disorders. *BMJ*. 2015;350:h715.
75. Spithoff S, Kahan M. Primary care management of alcohol use disorder and at-risk drinking: Part 2: counsel, prescribe, connect. *Can Fam Physician*. 2015; 61:515–21.
76. Rehm J, Anderson P, Manthey J, Shield KD, Struzzo P, Wojnar M, et al. Alcohol use disorders in primary health care – what do we know and where do we go? *Alcohol Alcohol*. 2015;51:422–7.
77. Rösner S, Hackl-Herwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. *Cochrane Database Syst Rev*. 2010;12:CD001867.
78. Lee J, Kresina TF, Campopiano M, Lubran R, Clark HW. Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care. *Biomed Res Int*. 2015;2015:137020.
79. Baros AM, Wright TM, Latham PK, Miller PM, Anton RF. Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. *Alcohol Alcohol*. 2008;43:192–7.
80. Aguilera MT, De la Sierra A, Coca A. Effect of alcohol abstinence on blood pressure. *Hypertension*. 1999;33:653–7.
81. Wallace P, Cutler S, Haines A. Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption. *BMJ*. 1988;297:663–8.
82. Rehm J, Anderson P, Gual A, Kraus L, Marmet S, Room R, et al. The tangible common denominator of substance use disorders: a reply to commentaries to Rehm et al. (2013). *Alcohol Alcohol*. 2014;49:118–22.
83. European Medicines Agency. Guideline on the Development of Medicinal Products for the Treatment of Alcohol Dependence. London: European Medicines Agency; 2010.
84. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension—its identification and epidemiology. *Nat Rev Nephrol*. 2013;9:51–8.
85. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Circulation*. 2008;117:e510–26.
86. Denolle T, Chamontin B, Doll G, Fauvel JP, Girerd X, Herpin D, et al. Management of resistant hypertension. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology. *Presse Med*. 2014;43:1325–31.
87. Organisation for Economic Co-operation and Development. Tackling Harmful Alcohol Use: Economics and Public Health Policy. Paris: Organisation for Economic Co-operation and Development; 2015.
88. Angus C, Latimer N, Preston L, Li J, Purshouse R. What are the implications for policy makers? A systematic review of the cost-effectiveness of screening and brief interventions for alcohol misuse in primary care. *Front Psychiatry*. 2014;5:114.

89. Angus C, Thomas C, Anderson P, Meier PS, Brennan A. Estimating the cost-effectiveness of brief interventions for heavy drinking in primary health care across Europe. *Eur J Public Health*. 2017;27(2):345–51.
90. Shield KD, Rylett M, Rehm J. Public health successes and missed opportunities, Trends in alcohol consumption and attributable mortality in the WHO European Region, 1990–2014. Copenhagen: WHO European Region; 2016.
91. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. *Methods for the Economic Evaluation of Health Care Programmes*. 3rd ed. New York: Oxford University Press; 2005.
92. Banegas JR, Graciani A, de la Cruz-Troca JJ, León-Muñoz LM, Guallar-Castillón P, Coca A, et al. Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study. *Hypertension*. 2012;60:898–905.
93. Godet-Thobie H, Vernay M, Noukpoape A, Salanave B, Malon A, Castebon K, et al. Niveau tensionnel moyen et prévalence de l'hypertension artérielle chez les adultes de 18 à 74 ans, ENNS 2006–2007. *BEH Thématique*. 2008;49–50:478–83.
94. Neuhauser H, Thamm M, Ellert U. Blutdruck in Deutschland 2008–2011. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). *Bundesgesundheitsbl*. 2013;56:795–801.
95. O'Brien E, Petrie J, Littler WA, de Swiet M, Padfield PL, Altman D, et al. The British Hypertension Society Protocol for the evaluation of blood pressure measuring devices. *J Hypertens*. 1993;11:S43–63.
96. CNESPS - Istituto Superiore di Sanita. Epidemiology and prevention of cerebrovascular and cardiovascular diseases. 2015. <http://www.cuore.iss.it/fattori/pressione.asp>. Accessed 7 Oct 2016.
97. Bianchini E, Brignoli O, Cricelli C, Cricelli I, Giustini S, Medea G, et al. Health Search - Istituto di Ricerca Della SIMG. Firenze: Società Italiana di Medicina Generale e delle Cure Primarie; 2014.
98. Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. *Int J Epidemiol*. 2005;34:413–21.
99. Llisterri JL, Rodriguez-Roca GC, Escobar C, Alonso-Moreno FJ, Prieto MA, Barrios V, et al. Treatment and blood pressure control in Spain during 2002–2010. *J Hypertens*. 2012;30:2425–31.
100. Catalá-López F, Ridao M, Sanfeliix-Gimeno G, Peiró S. Trends of uncontrolled blood pressure in Spain: an updated meta-regression analysis. *J Hypertens*. 2013;31:630–1.
101. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. *BMJ Open*. 2013;3:e003423.
102. Rehm J, Manthey J, Gual A, Wojnar M. Alcohol Dependence in Primary and Specialist Care in Europe - Data set. figshare. <https://dx.doi.org/10.6084/m9.figshare.2069585.v5>. Accessed 7 October 2016.
103. Pater C. The Blood Pressure "Uncertainty Range" - a pragmatic approach to overcome current diagnostic uncertainties (II). *Curr Control Trials Cardiovasc Med*. 2005;6:5.
104. Laatikainen T, Jula A, Kastarinen M, Salomaa V, Borodulin K, Harald K, et al. Verenpaineaset ja hoitotasapaino FINRISKI-tutkimusalueilla 1982–2012 [Blood pressure levels and therapeutic balance in FINRISK study areas in 1982–2012]. *Suomen Laakarilehti*. 2013;68:1803–9.
105. Koskinen S, Lundqvist A, Ristiluoma N. Terveys, toimintakyky ja hyvinvointi Suomessa 2011. Tampere: Juvenes Print - Suomen Yliopistopaino Oy; 2012.
106. World Health Organization. Global Health Estimates (GHE). 2016. http://www.who.int/healthinfo/global_burden_disease/en/. Accessed 19 July 2016.
107. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. *Bull World Health Organ*. 1994;72(3):429–45.
108. WHO Department of Information, Evidence and Research. WHO methods and data sources for global burden of disease estimates 2000–2015. Geneva: WHO; 2017. http://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf. Accessed 7 Aug 2017.
109. Rehm J, Gmel G, Sierra C, Gual A. Reduction of mortality following better detection of hypertension and alcohol problems in primary health care in Spain. *Adicciones*. 2016. Ahead of print.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

